questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du cytosquelette
Protéines de filaments intermédiaires
Protéines de filaments intermédiaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
Quantitative Structure-Activity Relationship
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines de filaments intermédiaires : Questions médicales les plus fréquentes",
"headline": "Protéines de filaments intermédiaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines de filaments intermédiaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-03",
"dateModified": "2025-02-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines de filaments intermédiaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines du cytosquelette",
"url": "https://questionsmedicales.fr/mesh/D003598",
"about": {
"@type": "MedicalCondition",
"name": "Protéines du cytosquelette",
"code": {
"@type": "MedicalCode",
"code": "D003598",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Desmine",
"alternateName": "Desmin",
"url": "https://questionsmedicales.fr/mesh/D003893",
"about": {
"@type": "MedicalCondition",
"name": "Desmine",
"code": {
"@type": "MedicalCode",
"code": "D003893",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine gliofibrillaire acide",
"alternateName": "Glial Fibrillary Acidic Protein",
"url": "https://questionsmedicales.fr/mesh/D005904",
"about": {
"@type": "MedicalCondition",
"name": "Protéine gliofibrillaire acide",
"code": {
"@type": "MedicalCode",
"code": "D005904",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Kératine-15",
"alternateName": "Keratin-15",
"url": "https://questionsmedicales.fr/mesh/D053569",
"about": {
"@type": "MedicalCondition",
"name": "Kératine-15",
"code": {
"@type": "MedicalCode",
"code": "D053569",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.450.300.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vimentine",
"alternateName": "Vimentin",
"url": "https://questionsmedicales.fr/mesh/D014746",
"about": {
"@type": "MedicalCondition",
"name": "Vimentine",
"code": {
"@type": "MedicalCode",
"code": "D014746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines de filaments intermédiaires",
"alternateName": "Intermediate Filament Proteins",
"code": {
"@type": "MedicalCode",
"code": "D007381",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sarah Köster",
"url": "https://questionsmedicales.fr/author/Sarah%20K%C3%B6ster",
"affiliation": {
"@type": "Organization",
"name": "Institute for X-Ray Physics, University of Goettingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany."
}
},
{
"@type": "Person",
"name": "Sandrine Etienne-Manneville",
"url": "https://questionsmedicales.fr/author/Sandrine%20Etienne-Manneville",
"affiliation": {
"@type": "Organization",
"name": "Cell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Équipe Labellisée Ligue Contre le Cancer, F-75015 Paris, France. Electronic address: setienne@pasteur.fr."
}
},
{
"@type": "Person",
"name": "Charlotta Lorenz",
"url": "https://questionsmedicales.fr/author/Charlotta%20Lorenz",
"affiliation": {
"@type": "Organization",
"name": "Institute for X-Ray Physics, University of Göttingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany."
}
},
{
"@type": "Person",
"name": "Anna V Schepers",
"url": "https://questionsmedicales.fr/author/Anna%20V%20Schepers",
"affiliation": {
"@type": "Organization",
"name": "Institute for X-Ray Physics, University of Göttingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany."
}
},
{
"@type": "Person",
"name": "Rudolf E Leube",
"url": "https://questionsmedicales.fr/author/Rudolf%20E%20Leube",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular and Cellular Anatomy, RWTH Aachen University, Aachen, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "PepQSAR: a comprehensive data source and information platform for peptide quantitative structure-activity relationships.",
"datePublished": "2022-12-06",
"url": "https://questionsmedicales.fr/article/36474016",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00726-022-03219-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quantitative Structure-Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors.",
"datePublished": "2022-08-26",
"url": "https://questionsmedicales.fr/article/36079779",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu14173521"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quantitative Structure-Activity Relationship Modeling of Pea Protein-Derived Acetylcholinesterase and Butyrylcholinesterase Inhibitory Peptides.",
"datePublished": "2023-10-19",
"url": "https://questionsmedicales.fr/article/37856319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jafc.3c04880"
}
},
{
"@type": "ScholarlyArticle",
"name": "Data-Driven Quantitative Structure-Activity Relationship Modeling for Human Carcinogenicity by Chronic Oral Exposure.",
"datePublished": "2023-04-11",
"url": "https://questionsmedicales.fr/article/37040559",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.est.3c00648"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ensemble Learning, Deep Learning-Based and Molecular Descriptor-Based Quantitative Structure-Activity Relationships.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36903654",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules28052410"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du cytosquelette",
"item": "https://questionsmedicales.fr/mesh/D003598"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de filaments intermédiaires",
"item": "https://questionsmedicales.fr/mesh/D007381"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines de filaments intermédiaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines de filaments intermédiaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Général",
"headline": "Général sur Protéines de filaments intermédiaires",
"description": "Erreur lors de la génération.",
"url": "https://questionsmedicales.fr/mesh/D007381?mesh_terms=Quantitative+Structure-Activity+Relationship&page=2#section-général"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Erreur lors de la génération.",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Veuillez réessayer ultérieurement."
}
}
]
}
]
}
Peptide quantitative structure-activity relationships (pQSARs) have been widely applied to the statistical modeling and empirical prediction of peptide activity, property and feature. In the procedure...
Stevioside, one of the natural sweeteners extracted from stevia leaves, and its derivatives are considered to have numerous beneficial pharmacological properties, including the inhibition of activated...
The aim of this work was to determine the structural requirements for peptides that inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities. The data set used consisted of 19 ...
Traditional methodologies for assessing chemical toxicity are expensive and time-consuming. Computational modeling approaches have emerged as low-cost alternatives, especially those used to develop qu...
A deep learning-based quantitative structure-activity relationship analysis, namely the molecular image-based DeepSNAP-deep learning method, can successfully and automatically capture the spatial and ...
The photocatalytic degradation behavior of aromatic micro-pollutants (AMPs) exhibits complexity and uncertainty, which mainly depends on the properties of different substituents on benzene. And with s...
Chronic myelogenous leukemia (CML) which is resulted from the BCR-ABL tyrosine kinase (TK) chimeric oncoprotein, is a malignant clonal disorder of hematopoietic stem cells. Imatinib is used as an inhi...
The growing concentrations of micropollutants in aquatic ecosystems are a global water quality issue. Understanding micropollutants varied chemical composition and potency is essential to solving this...
Previous studies have reported that zerovalent iron (ZVI) can reduce several aliphatic groups of disinfection byproducts (DBPs) (e.g., haloacetic acids and haloacetamides) effectively, and the removal...
The search for chemical hit material is a lengthy and increasingly expensive drug discovery process. To improve it, ligand-based quantitative structure-activity relationship models have been broadly a...
